229 patients with unilateral or bilateral and mild-moderate knee osteoarthritis (Kellgren-Lawrence Grade 2-3) were included in this study to determine the comparative efficacy of extended-release triamcinolone acetonide compared to immediate-release triamcinolone acetonide. Patients were randomized into 1 of 3 groups receiving extended-release triamcinolone acetonide (10, 40 or 60 mg) or to the control group receiving 40 mg of immediate-release triamcinolone acetonide. Mean daily pain was measured over a 12 week period. Results indicated that 40 mg extended-release triamcinolone acetonide significantly reduced pain compared to immediate-release at 8 and 10 weeks.